Date: 2017-02-07
Type of information: Nomination
Compound: member of the board of directors
Company: Minoryx Therapeutics (Spain)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On February 8, 2017, Minoryx Therapeutics announced that Dr Claude Nicaise has joined its board of directors as an independent member. Dr Nicaise has over 30 years experience in developing worldwide regulatory strategy in the pharmaceutical and biotechnology industries. He is the owner of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies.
- Currently, Dr. Nicaise is board member at Sarepta Therapeutics. Between 2008 and 2014 he was senior vice president of strategic development and global regulatory affairs at Alexion Pharmaceuticals. From 1983 to 2008, he worked in various positions at BMS, including vice-president of global development, vice-president worldwide regulatory science and strategy, as well as leadership positions in the oncology, infectious diseases and neuroscience departments. Dr Nicaise received his medical degree in 1976 from the Université Libre de Bruxelles in Belgium.
- Dr Nicaise has authored over a hundred papers and abstracts. He is member of a number of professional societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the European Society for Medical Oncology, the American Society for Microbiology and the American Society of Hematology.
Financial terms:
Latest news:
Is general: Yes
